В зоне риска. Тонкости защиты женского организма. Как ВПЧ проникает в наш организм, чем он опасен и что поможет избежать последствий

27. Kojic E.M., Cu-Uvin S. Update: human papillomavirus infection remains highly prevalent and persistent among HIV-infected individuals. Curr Opin Oncol 2007; 19:464–9.

28. Martin M.P., Borecki I.B., Zhang Z., et al. HLA-Cw group 1 ligands for KIR increase susceptibility to invasive cervical cancer. Immunogenetics 2010; 62:761–5.

29. Cox J.T. В: Lonky N., ed. Management of precursor lesions of cervical carcinoma: history, host defense, and a survey of modalities. Obstet Gynecol Clin North Am 2002; 29(4):751–85.

30. Gollnick H., Barrasso R., Jappe U., et al. Safety and efficacy of imiquimod 5 % cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. Int J STD AIDS2001; 12:22–8.

31. Ho GYF, Bierman R., Beardsley L., Chang C.J., Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423–8.

32. Einstein M.H., Burk R.D. Persistent human papillomavirus infection: definitions and clinical implications. Papillomavirus Rep 2001; 12:119–23.

33. Ostor A.G. Natural history of CIN: a critical review. Int J Gynecol Pathol 1993; 12:186–92.

34. Burghardt E., Ostor A.G. Site and origin of squamous cervical cancer: a histomorphologic study. Obstet Gynecol 1983; 62:117–26.

35. Selvaggi S.M. Reporting of atypical squamous cells, cannot exclude a high-grade squamous intraepithelial lesion (ASC-H) on cervical samples: is it significant? Diagn Cytopathol 2003; 29:38–41.

36. Hopman E.H., Kenemans P., Helmerhorst T.J.M. Positive predictive rate of colposcopic examination of the cervix uteri: an overview of the literature. Obstet Gynecol Survey 1998; 53:97–106.

37. Gage J.C., Hanson V.W., Abbey K., et al.; The ASCUS LSIL Triage Study (ALTS) Group. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 2006; 108(2):264–72.

38. Sze E., Rosenzweig B., Birenbaum D., et al. Excisional conization of the cervix-uteri. J Gynecol Surg 1989; 5:325–31.

39. Ferenczy A., Choukroun D., Arseneau J. Loop electrosurgical excision procedure for squamous intraepithelial lesions of the cervix: advantages and potential pitfalls. Obstet Gynecol 1996; 87:332–7.

40. Davey D.D., Neal M.H., Wilbur D.C., Colgan T.J., Styer P.E., Mody D.R. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med 2004; 128:1224–9.

41. Stoler M.H., Wright T.C. Jr, Sharma A., Apple R., Gutekunst K., Wright T.L.; the ATHENA (Addressing THE Need for Advanced HPV Diagnostics) HPV Study Group. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 2011; 135:468–75.

42. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003; 188:1383–92.

43. Jones B.A., Davey D.D. Quality management in gynecologic cytology using interlaboratory comparison. Arch Pathol Lab Med 2000; 124:672–81.

44. Arbyn M., Sasieni P., Meijer C.J., Clavel C., Koliopoulos G., Dillner J. Chapter 9: clinical applications of HPV testing: a summary of metaanalyses. Vaccine 2006; 24(suppl 3): S78–89.

45. Moscicki A.B., Ma Y., Wibbelsman C., et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol 2010; 116(6):1373–80.

46. Monteiro D.L., Trajano A.J., Russomano F.B., Silva K.S. Prognosis of intraepithelial cervical lesion during adolescence in up to two years of follow-up. J Pediatr Adolesc Gynecol 2010; 23(4):230–6.

47. Sherman M.E., Schiffman M.H., Lorincz A.T., et al. Toward objective quality assurance in cervical cytopathology. Correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types. Am J Clin Pathol 1994; 102(2):182–7.

48. Koeneman M.M., Essers B.A., Gerestein C.G., van de Sande A.J., Litjens R.J., Boskamp D., Goossens M.F., Beekhuizen H.J., Kruitwagen R.F., Kruse A.J., Dirksen C.D. Treatment of Cervical Intraepithelial Neoplasia: Patients Preferences for Surgery or Immunotherapy with Imiquimod J Immunother. 2017 Feb 17.

49. Teymouri M., Pirro M., Johnston T.P., Sahebkar A. Curcumin as a multifaceted compound against human papilloma virus infection and cervical cancers: A review of chemistry, cellular, molecular, and preclinical features. Biofactors. 2017 May 6; 43(3):331–346.

50. Leda Gattoc, Paula M. Frew, Shontell N. Thomas, Kirk A. Easley, Laura Ward, H-H Sherry Chow, Chiemi A. Ura, Lisa Flowers Phase I dose-escalation trial of intravaginal curcumin in women for cervical dysplasia Open Access J Clin Trials. 2017; 9: 1–10. Published online 2016 Dec 22. doi: 10.2147/OAJCT.S105010.